|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Allergan |
|---|---|
| Information provided by: | Allergan |
| ClinicalTrials.gov Identifier: | NCT00693420 |
Purpose
This study evaluates the safety and effectiveness of topical bimatoprost solution for enhancing eyelash prominence.
| Condition | Intervention | Phase |
|---|---|---|
|
Eyelashes |
Drug: Bimatoprost 0.03% sterile solution Drug: vehicle sterile solution |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
| Enrollment: | 278 |
| Study Start Date: | April 2007 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Bimatoprost 0.03% solution
|
Drug: Bimatoprost 0.03% sterile solution
Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
|
|
2: Placebo Comparator
Vehicle solution
|
Drug: vehicle sterile solution
Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, California | |
| San Diego, California, United States | |
| Canada, British Columbia | |
| Vancouver, British Columbia, Canada | |
| Study Director: | Medical Director | Allergan |
More Information
| Responsible Party: | Allergan, Inc. ( Therapeutic Area Head ) |
| Study ID Numbers: | 192024-032 |
| Study First Received: | June 5, 2008 |
| Results First Received: | January 14, 2009 |
| Last Updated: | March 26, 2009 |
| ClinicalTrials.gov Identifier: | NCT00693420 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Bimatoprost Therapeutic Uses Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |